NCT02728349CompletedPhase 1

Phase 1 Trial of Tolerance and Pharmacokinetic of Chlorogenic Acid for Injection in the Advanced Glioblastoma Patients

Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd1 site in 1 country26 target enrollmentStarted: April 12, 2016Last updated: November 1, 2018

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Completed
Sponsor
Enrollment: 26
Locations: 1
Primary Endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0，grade ≥3 (DLT)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

The purpose of this study:

Determining the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), pharmacokinetics characteristic, and dosage regimen of phase II/III of Chlorogenic acid for injection in the advanced Glioblastoma Patients ;

Detailed Description

Investigate the tolerance of Chlorogenic acid for injection in human body, determine the Maximum Tolerated Dose (MTD) and Dose-Limiting Toxicity (DLT) of Chlorogenic acid for injection in the advanced Glioblastoma Patients ;
Determine the human pharmacokinetics characteristic of Chlorogenic acid for injection;
Preliminary observation the effectiveness and effective dose;
Provide the basis for the dosage regimen of phase II/III.

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to 65 Years (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Patients with pathologic or/and FNAC confirmation of advanced glioblastoma(WHO,III-IV grade) but without effective treatment or with treatment failure;
•Between 18 and 65 years of age, KPS≥40;
•According to RANO(2010), the parents will be eligible if one of the following conditions apply: steroid dose increased or stable,the enhanced tumor lesion increased more than 25%; the unenhanced tumor lesion increased because of the progressive tumor,even if the lesion was unmeasurable.
•Life expectancy of at least three (3) months at the enrollment;
•Patients who have sufficient baseline organ function and whose laboratory data can meet the following criteria at the enrollment:
•PLT count≥100×10~9/L, 2)WLB count≥4.0×10~9/L and ≤12×10~9/L, 3)Neutrophil granulocyte count≥2.0×10~9/L, 4)HGB count≥90g/L, 5)Total bilirubin <=1.5 times of ULN, 6)ALT/AST ≤2.5 times of ULN, 7)SCr≤1.5 times of ULN, 8)Normal ECG with LVEF (≥50%) measured by echocardiography; 6.Female patients with negative pregnant test, and male/female patients of reproductive age without pregnancy planning in the next 12 months; 7.Volunteered for the phase 1 trial and sign the informed consent without protest;

Exclusion Criteria

•Patients who have received large area radiotherapy （>30% marrow capacity）;
•Without pathologic or/and FNAC confirmation of advanced glioblastoma;
•Patients who has primary immunodeficiency diseases；
•Patients who suffer from other serious complication, such as uncontrollable infection, myocardial infarction within the past 6 months at the enrollment , uncontrollable hypertension ,thromboembolism and etc.;
•Patients who have received the therapy of chemotherapy or radical radiotherapy within 4 weeks before enrollment;
•Patients who have used nitrosoureas drug or mitomycin within 6 weeks or tyrosine kinase inhibitor within 2 weeks before enrollment;
•Patients who have received therapy of major surgery within 4 weeks or biopsy surgery within 2 weeks before enrollment;
•Patients who experience grade 2 or more than grade 2 toxicity caused by the past therapies;
•Patients who have history of drug abuse;
•Uncontrollable psychopaths；
•Uncontrollable diabetes；
•Pregnant or breast-feeding women, or patients(male and female) who have pregnancy plan;
•Patients who had received a therapy of another investigational drug within 12 weeks or patients who are still in another clinical trial at the enrollment;
•Known active hepatitis B/hepatitis C, positive HIV/ syphilis antibody;
•Patient who need long term treatment of cortical hormone or other immunosuppressive drugs such as visceral organ transplanters;
•Allergic to the investigational drug;
•Other patients judged ineligible for enrollment in the study by the investigator (sub-investigator).
•Patients who have received the therapy of adrenal steroid hormones within 1 week before enrollment or will receive the therapy for a long period time，except for Corticosteroid nasal spray，Inhaled Steroid and Topical steroids .

Arms & Interventions

Chlorgenic acid, Treatment, powder

Experimental

Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.

Intervention: Chlorogenic acid (Drug)

Outcomes

Primary Outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0，grade ≥3 (DLT)